Navigation Links
Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
Date:11/12/2008

ificant treatment gap and meet a major unmet need."

Clinical Study Details and Results

In this study, 20 patients were identified with stable coronary artery disease that were treated with chronic clopidogrel (75mg) and aspirin therapy and have HPR. These clopidogrel non-responders were treated with one oral dose of PRT060128 (60mg) at 12 to 16 hours after the previous day's dose of clopidogrel. Platelet aggregation was determined by ADP and collagen-induced aggregation and pharmacodynamic assays. The mean platelet reactivity was reduced from the highest (non-responder) to lowest (normal responder) tertile, following dosing with PRT060128, and achieved the predefined endpoint. Inhibition of thrombosis was highly significant in these non-responder patients. The oral dose of PRT060128 chosen for this study is at the low end of the dosing range that will be evaluated in the Portola's upcoming Phase II study.

"We are encouraged by these clinical results suggesting PRT060128 may be effective and well tolerated in clopidogrel non-responders," said Charles Homcy, M.D., president and chief executive officer of Portola. "This novel agent has immediate, predictable and reversible platelet inhibition that appears to overcome HPR in non-responders and other major limitations of clopidogrel."

Previously conducted clinical trials showed that PRT060128 was well- tolerated without serious adverse events. In addition, PRT060128 showed predictable, dose-dependent platelet inhibition. Portola expects to begin patient enrollment in an 800 patient Phase II study with the IV and oral forms of PRT060128 for prevention of thrombotic events in patients undergoing non- urgent percutaneous coronary interventions (PCI) before the end of this year.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
4. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
5. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
6. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
7. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
10. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
11. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/18/2014)... news release is available in French . ... could revolutionize surgical practice and regenerative medicine. A team ... et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from ... Paris 13), has just demonstrated that the principle of ... in vivo to repair soft-tissue organs and tissues. This ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... Prompts Extension of Promotion -, DENVER, July ... of functional foods, beverages and nutritional,supplements, announced that ... of the $1 million sales goal for the ... opportunity to earn,significant bonuses in July., John ...
... hardest hit states by this legislation, WASHINGTON, July ... significant funding cuts under legislation being,considered in Congress, according ... As Congress considers ways to halt the impending cut ... Medicare Advantage program to,pay for the fix. Legislation currently ...
... July 2 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, ... in the United States,District Court, Northern District of ... (Dornier) and NewStar Lasers,Inc. d/b/a CoolTouch, Inc. (CoolTouch)., ...
... ushers in The Art of Condoms (FDA-approved), as the ... latest hi-tech advancement in safe-sex., ... of designer-condoms. Remarkably shaped condoms,including the look-alike Dolphin Condom(TM) and ... designers could only dream,of making before. The Dolphin(TM) has all ...
... for environment, MELROSE PARK, Ill., July 2 ... that it has surpassed the,sale of 1 million green ... "We are seeing more and more people buying ... Jewel-Osco. "This is,likely due to the heightened awareness about ...
... disease can save some vision, experts say , , WEDNESDAY, ... to end in blindness, two new studies suggest. , ... for glaucoma has better outcomes than using glaucoma drainage ... end-stage glaucoma can be successfully treated. Both studies were ...
Cached Medicine News:Health News:XELR8 Holdings Announces Continuation of 'XELR8 To A Million' Promotion 2Health News:Proposed Congressional Legislation Would Cut $784 Million From the Medicare Advantage Program in New York 2Health News:VNUS Medical Technologies, Inc. Files Patent Infringement Lawsuits Against Biolitec, Dornier and CoolTouch 2Health News:The New Condom That Breaks - - - the Mold. 2Health News:Jewel-Osco: 1 Million Reusable Shopping Bags Sold 2Health News:Glaucoma Treatment Can Prevent Blindness 2Health News:Glaucoma Treatment Can Prevent Blindness 3
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle....
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
8 mm curved blade. Cutting edge on inside of curve. Flat handle....
For use with N4096 R, N4097 R and N4098 R. 18 mm wide x 167 mm long. Ten per package. Designated most popular model or size....
Medicine Products: